-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25

Benzinga·12/11/2025 13:15:09
Listen to the news
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.